Registrieren

India's family-run pharmaceutical companies are entering a new phase as the next generation takes on larger leadership roles and steers businesses towards complex generics, peptides, biologics, contract manufacturing and advanced therapeutics. Laurus Labs, Granules India, Bharat Biotech, Sun Pharma and Torrent Pharma are investing in capabilities that require greater scientific expertise, significant capital and longer gestation periods. The key question is whether the successors can turn these long-term bets into sustainable growth and create lasting value for investors.